https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/336 Fri, 24 Jul 2026 22:39:26 GMT 2026-07-24T22:39:26Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/219178 Title: Re: Marmor et al.: Recommendations on screening for hydroxychloroquine retinopathy (2025 Revision) (Ophthalmology. 2026;133:439-450) REPLY Authors: Marmor, Michael F.; Ahn, Seong Joon; Ehlers, Justis P.; Melles, Ronald B.; Mieler, William F.; Sarraf, David; Yusuf, Imran H. Wed, 01 Jul 2026 00:00:00 GMT https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/219178 2026-07-01T00:00:00Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/219376 Title: Analysis of full-field electroretinography parameters and potential for monitoring functional retinal deterioration in unilateral retinal vasculitis Authors: Park, Sungwho; Yoo, Woong-Sun; Karaca, Irmak; Khojasteh, Hassan; Akhavanrezayat, Amir; Uludag, Gunay; Tran, Anh Ngoc Tram; Lyu, Xun; Yasar, Cigdem; Ongpalakorn, Prapatsorn; Mobasserian, Azadeh; Bromeo, Albert John; Ghoraba, Hashem; Shin, Yong Un; Thng, Zheng Xian; Gupta, Ankur Sudhir; Khatri (kc), Anadi; Hung, Jia-Horung; Or, Christopher; Do, Diana V.; Nguyen, Quan Dong Abstract: To elucidate changes of full-field electroretinography (ffERG) tests in active unilateral retinal vasculitis, using the unaffected fellow eye as an internal control. Despite no significant differences in best corrected visual acuity (p=0.100) or central subfield macular thickness (p=0.084) at baseline, ffERG showed significant reductions in five of eight amplitudes (i.e. DA10 a-wave, p<0.001) and delays in six of eight implicit times (i.e. light-adapted Flicker, p=0.002). At follow-up ffERG, following management for retinal vasculitis, the implicit times normalised, coinciding with inflammation reduction. However, the amplitude reductions persisted. In ffERG, the implicit time might be a sensitive biomarker for retinal vasculitis activity and the amplitude might be one for permanent functional loss. Wed, 01 Jul 2026 00:00:00 GMT https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/219376 2026-07-01T00:00:00Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/213191 Title: Incidence of glaucoma in patients with systemic lupus erythematosus: a nationwide cohort study in South Korea Authors: Kim, Ji Hong; Kim, Yunjin; Oraha, Kathy Michelle; Park, Hae Min; Kim, Yu Jeong; Lim, Han Woong; Sung, Yoon-Kyoung; Welsbie, Derek S.; Lee, Won June Abstract: Background/aims To assess the incidence of glaucoma in patients with systemic lupus erythematosus (SLE) and to identify associated risk factors using a nationwide population-based cohort. Methods This retrospective cohort study analysed data from the Korean National Health Insurance Service (2008-2022). A total of 9682 patients with SLE were identified using ICD-10 code M32 and rare intractable disease code V136 and matched 1:1 to non-SLE controls by age and sex. The incidence of glaucoma (ICD-10 codes H40 and H42) and glaucoma suspect (H40.0) was assessed. Multivariate logistic regression was used to identify risk factors for glaucoma, including long-term corticosteroid use (>= 180 days). Results The incidence of glaucoma was significantly higher in the SLE group than in controls (11.34% vs 3.74%; p<0.0001), with a greater prevalence in younger patients (<40 years) and females. Glaucoma suspect cases were also more common in the SLE group (35.56% vs 30.25%; p<0.0001). SLE was independently associated with glaucoma (adjusted OR: 2.00, 95% CI 1.69 to 2.38), and prolonged corticosteroid use further increased the risk (OR: 1.75, 95% CI 1.51 to 2.02). Annual incidence trends showed a rising pattern over time, especially among SLE patients. Conclusions SLE is associated with an increased risk of glaucoma, particularly among younger individuals and females. Prolonged corticosteroid therapy significantly contributes to this risk. These findings support the need for regular ophthalmic screening and judicious corticosteroid management in patients with SLE. Mon, 01 Jun 2026 00:00:00 GMT https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/213191 2026-06-01T00:00:00Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/219448 Title: Clinical Utility of an AI-Based Retinal Imaging Model for Cardiovascular Risk Prediction in Hypertensive Retinopathy Authors: Nam, Dongjin; Jang, Yong-hwan; Lee, Yongseok; Seo, Jaewon; Thakur, Sahil; Nusinovici, Simon; Kim, Moonsu; Shin, Yong-un; Park, Hwan-cheol; Hwang, Sunjin Abstract: Objective This study presents an independent clinical evaluation of Dr.Noon CVD, a commercially developed artificial intelligence (AI)-based retinal imaging model that estimates cardiovascular disease (CVD) risk. We assessed whether the model can effectively evaluate CVD risk in patients with hypertensive retinopathy (HR), a population in which the applicability of conventional CVD risk models remains uncertain. Methods We retrospectively analyzed 102 age-matched patients from Hanyang University Guri Hospital and classified them into normal (Group 1), low-grade HR (Group 2), and high-grade HR (Group 3) groups using Keith–Wagener–Barker grading. CVD risks were assessed via Dr.Noon CVD score and conventional risk scores (PREVENT, PCE, SCORE2, SCORE2-Diabetes). Associations and predictive performance were evaluated using logistic regression, area under the ROC curve (AUC), and net reclassification improvement (NRI). Results Low-density lipoprotein cholesterol, estimated glomerular filtration rate, and blood pressure were significantly higher in the HR groups versus Group 1 ( p < 0.05). Dr.Noon CVD scores differed significantly across HR grades ( p = 0.002), particularly between Groups 3 and 1 ( p = 0.002), while conventional scores showed no significant separation ( p > 0.1). Higher Dr.Noon CVD scores were associated with Group 3 in both unadjusted (OR = 1.11; p = 0.001) and adjusted models (OR = 1.33; p < 0.001). Scores remained stable between acute and chronic HR ( p = 0.966). Combining Dr.Noon CVD score with conventional models improved CVD risk classification (higher AUC and NRI). Conclusions Dr.Noon CVD identified elevated CVD risk in HR patients and enhanced stratification when combined with existing models. These results support the use of retinal biomarkers in CVD risk assessment and the need for multidisciplinary management. Mon, 01 Jun 2026 00:00:00 GMT https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/219448 2026-06-01T00:00:00Z